About AdvanCell
AdvanCell is a company based in Sydney (Australia) founded in 2019 by Andrew Adamovich.. AdvanCell has raised $129.42 million across 4 funding rounds from investors including Abingworth, Department of Health, Disability and Ageing and SV Health Investors. AdvanCell offers products and services including Alpha 212. AdvanCell operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, Mariana Oncology, Ariceum Therapeutics and Lantheus, among others.
- Headquarter Sydney, Australia
- Founders Andrew Adamovich
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Advancell Isotopes Pty Limited
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$129.42 M (USD)
in 4 rounds
-
Latest Funding Round
$18 M (USD), Grant
Apr 13, 2025
-
Investors
Abingworth
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AdvanCell
AdvanCell offers a comprehensive portfolio of products and services, including Alpha 212. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides cGMP isotope for targeted alpha therapy in cancer treatment development.
Unlock access to complete
Funding Insights of AdvanCell
AdvanCell has successfully raised a total of $129.42M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $18 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $18.0M
-
First Round
First Round
(24 Aug 2022)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2025 | Amount | Grant - AdvanCell | Valuation |
investors |
|
| Feb, 2025 | Amount | Series C - AdvanCell | Valuation | SV Health Investors , Sanofi Ventures | |
| Dec, 2023 | Amount | Series B - AdvanCell | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AdvanCell
AdvanCell has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Abingworth, Department of Health, Disability and Ageing and SV Health Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on early-stage healthcare startups
|
Founded Year | Domain | Location | |
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AdvanCell
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AdvanCell
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Advancell Comparisons
Competitors of AdvanCell
AdvanCell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, Mariana Oncology, Ariceum Therapeutics and Lantheus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Developer of molecular imaging systems and radio-pharmaceuticals
|
|
| domain | founded_year | HQ Location |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for systemic targeted radiation therapy to treat cancer
|
|
| domain | founded_year | HQ Location |
Developer of diagnostic imaging agents and targeted therapeutics
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Advancell
Frequently Asked Questions about AdvanCell
When was AdvanCell founded?
AdvanCell was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Where is AdvanCell located?
AdvanCell is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Who is the current CEO of AdvanCell?
Andrew Adamovich is the current CEO of AdvanCell. They have also founded this company.
Is AdvanCell a funded company?
AdvanCell is a funded company, having raised a total of $129.42M across 4 funding rounds to date. The company's 1st funding round was a Series B of $5M, raised on Aug 24, 2022.
What does AdvanCell do?
The company was founded in 2019 and is based in Sydney, Australia, within the radiopharmaceutical sector. Targeted alpha therapies for treating cancers including prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovarian types are developed. Operations center on a proprietary Pb production technology, which enables access to alpha isotopes for advancing clinical drug development.
Who are the top competitors of AdvanCell?
AdvanCell's top competitors include Advanced Accelerator Applications, SOFIE and Mariana Oncology.
What products or services does AdvanCell offer?
AdvanCell offers Alpha 212.
Who are AdvanCell's investors?
AdvanCell has 8 investors. Key investors include Abingworth, Department of Health, Disability and Ageing, SV Health Investors, Sanofi Ventures, and SymBiosis.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.